T Cell News and Research

Latest T Cell News and Research

Tiny proteins prevent bacterial gene transcription

In the search for new antibiotics, researchers are taking an unusual approach: They are developing peptides, short chains of protein building blocks that effectively inhibit a key enzyme of bacterial metabolism.

10 Apr 2013

CYP1B1 protein prevents head and neck cancers, say researchers

Head and neck cancers typically begin in squamous cells that line moist surfaces inside the mouth, nose and throat. Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most common type of cancer in the United States, and it is sometimes preceded by the appearance of changes inside the oral cavity called precancerous lesions.

10 Apr 2013

New chemotherapy regimen appears to produce minimal side effects in lung cancer patients

A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors, according findings to be presented by Fox Chase Cancer Center researchers at the AACR Annual Meeting 2013 on Tuesday, April 9.

10 Apr 2013

Researchers discover novel protein that governs metastasis and chemoresistance in pediatric bone cancer

Human osteosarcoma samples are hard to come by, making the disease difficult to study. However, K9 bone cancer is genetically indistinguishable from the human form of the disease, and over 10,000 canine patients develop the disease every year.

10 Apr 2013

New combination therapy could help restore vision

Researchers have discovered that using two kinds of therapy in tandem may be a knockout combo against inherited disorders that cause blindness. While their study focused on man's best friend, the treatment could help restore vision in people, too.

10 Apr 2013

New study shows combination therapy is effective in treating sarcoma tumors

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida have found that when given together, a two-drug combination acts synergistically in test animals modeled with sarcoma tumors.

10 Apr 2013

Tumors with excess copies of MYCN highly sensitive to BET bromodomain inhibitors, researchers find

An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor, a difficult-to-treat, early childhood cancer, is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors, Dana-Farber/Children's Hospital Cancer Center scientists will report at the annual meeting of the American Association for Cancer Research in Washington, April 6-10.

10 Apr 2013

First combination treatment of microwave ablation, radiotherapy performed on 52-year-old patient

Dr. Hudayi Korkusuz, a radiologist at the Department of Nuclear Medicine, has conducted the first combination treatment of microwave ablation and radiotherapy.

10 Apr 2013

AACR recognizes UT MD Anderson professor for contributions to cancer research

Guillermina "Gigi" Lozano, Ph.D., chair and professor in the Department of Genetics at The University of Texas MD Anderson Cancer Center, is the recipient of the 16th annual Women in Cancer Research Charlotte Friend Memorial Lectureship awarded by The American Association for Cancer Research, recognizing her contributions to the field of cancer research and the advancement of women in science.

10 Apr 2013

Jeffrey Epstein VI Foundation helps develop mathematical model to study evolution of cancer

The Jeffrey Epstein VI Foundation, a science foundation based in New York City, has helped finance the first mathematical model of how human cancer cells evolve, and more specifically, how they evolve to become immune to inhibitor drug therapy, a popular alternative to chemotherapy.

10 Apr 2013

MD Anderson scientists demonstrate new way to restore tumor suppression

Tumor suppression, the family business of the sibling genes p53, p63 and p73, is undermined from within by the split personalities of p63 and p73, which each produce protein forms that not only block the work of the other two genes but also shut down its own cancer-stifling fraternal twin.

10 Apr 2013

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.

10 Apr 2013

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

A molecular signature index technology that can lead to better radiation therapy decisions for patients with cancer is being developed into a reliable radiosensitivity test by CvergenX, Inc., an advanced cancer diagnostics company.

10 Apr 2013

Elekta's Versa HD system accelerates radiation delivery to new levels

Featuring a revolutionary combination of speed and accuracy, Elekta's new Versa HD system will help clinicians at The Christie NHS Foundation Trust (Withington, Manchester) maximize the precision of therapeutic beams on the tumor target, while also accelerating radiation delivery to new levels.

From Elekta 10 Apr 2013

Cell>Point reports encouraging results from Phase 2a cardiovascular clinical study of 99mTc-EC-G

Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri.

10 Apr 2013

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.

10 Apr 2013

Findings could help develop new ways to predict risks of tobacco-associated cancers

Believe it or not, while researchers have explored which genes are mutated in each type of tobacco-associated cancer, until now no one had thought to look across these types for common genes that might predict patient outcomes. Results presented at the AACR Annual Meeting 2013 show that in lung and bladder cancers, genes related to the regulation of the cell cycle are associated with poor patient outcomes.

10 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Multiple genes strongly contribute to risk for schizophrenia

Multiple genes contribute to risk for schizophrenia and appear to function in pathways related to transmission of signals in the brain and immunity, according to an international study led by Virginia Commonwealth University School of Pharmacy researchers.

10 Apr 2013

Exposure to traffic-related air pollution associated with increases in rare childhood cancers

Scientists from UCLA's Fielding School of Public Health led by Julia Heck, an assistant researcher in the school's epidemiology department and a member of UCLA's Jonsson Comprehensive Cancer Center, have found a possible link between exposure to traffic-related air pollution and several childhood cancers.

10 Apr 2013

T Cell News and Research

Latest T Cell News and Research

Tiny proteins prevent bacterial gene transcription

CYP1B1 protein prevents head and neck cancers, say researchers

New chemotherapy regimen appears to produce minimal side effects in lung cancer patients

Researchers discover novel protein that governs metastasis and chemoresistance in pediatric bone cancer

New combination therapy could help restore vision

New study shows combination therapy is effective in treating sarcoma tumors

Tumors with excess copies of MYCN highly sensitive to BET bromodomain inhibitors, researchers find

First combination treatment of microwave ablation, radiotherapy performed on 52-year-old patient

AACR recognizes UT MD Anderson professor for contributions to cancer research

Jeffrey Epstein VI Foundation helps develop mathematical model to study evolution of cancer

MD Anderson scientists demonstrate new way to restore tumor suppression

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

Elekta's Versa HD system accelerates radiation delivery to new levels

Cell>Point reports encouraging results from Phase 2a cardiovascular clinical study of 99mTc-EC-G

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

Findings could help develop new ways to predict risks of tobacco-associated cancers

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Multiple genes strongly contribute to risk for schizophrenia

Exposure to traffic-related air pollution associated with increases in rare childhood cancers

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in